German corporation Bayer has announced that its four most promising drugs, led by newly-launched anti-clotting pill Xarelto, may account for combined annual sales of as much as $6.5 billion, according to a Reuters report.
The report says Bayer’s healthcare division is aiming for sales of roughly $26.2 billion in 2014, up from $22.4 billion last year.
The company said prescription drug sales were set to rise to about $15 billion by 2014, up 16 percent from 2011, fueled largely by new product ...
continue reading...